menu
    • menu

    Company profile for Bit Bio

    Pfanstiehl, a global leader in the manufacture of cGMP high purity, low endotoxin, low metals (HPLE-LM)TM injectable grade excipients.

    Virtual Booth

    Contact Supplier

    Global Pharma Healthcare: Setting the global benchmark in quality, innovation, and care

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    Phyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.

    Virtual Booth

    Contact Supplier

    Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Founded in 2016 by Dr Mark Kotter, Bit Bio (formerly Elpis Biomed) is an award-winning spinout from the University of Cambridge. By applying an engineering approach to synthetic and stem cell biology, Mark and his team have developed proprietary technologies for the efficient and consistent reprogramming of human cells used in research, drug discovery, and cell therapy. ‘Bit Bio’ represents the two fields — coding and bi...
    Founded in 2016 by Dr Mark Kotter, Bit Bio (formerly Elpis Biomed) is an award-winning spinout from the University of Cambridge. By applying an engineering approach to synthetic and stem cell biology, Mark and his team have developed proprietary technologies for the efficient and consistent reprogramming of human cells used in research, drug discovery, and cell therapy. ‘Bit Bio’ represents the two fields — coding and biology — that determine the Identity of every human cell. Ultimately, bits are the building blocks of code, just as cells are the building blocks of life.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Bit Biounitedkingdom_new Flag
    Country
    Country
    United Kingdom
    Address
    Address
    Discovery Drive Cambridge Biomedical Campus Cambridge, Cambridgeshire CB2 0A...
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.bit.bio/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/bitbioltd
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/bitbioltd

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    M&G Leads $50M Funding For Bit.Bio In UK Drug Discovery
    M&G Leads $50M Funding For Bit.Bio In UK Drug Discovery

    09 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/mg-champions-uk-innovation-in-drug-discovery-by-leading-us50-million-funding-round-for-biotech-company-bitbio-302657492.html

    PR NEWSWIRE
    09 Jan 2026
    Share Share
    Südhof, bit.bio CEO Fireside on Programming Human Cells
    Südhof, bit.bio CEO Fireside on Programming Human Cells

    29 Apr 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240429835327/en

    BUSINESSWIRE
    29 Apr 2024
    Share Share
    Bit.bio Appoints Kathryn Corzo as Chief Operating Officer
    Bit.bio Appoints Kathryn Corzo as Chief Operating Officer

    17 Nov 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20211117005057/en

    BUSINESSWIRE
    17 Nov 2021
    Share Share
    Bit.bio raises $103m through series B round to develop cell therapies
    Bit.bio raises $103m through series B round to develop cell therapies

    08 Nov 2021

    // PHARMACEUTICAL-TECHNOLOGY

    https://www.pharmaceutical-technology.com/news/bit-bio-103m-series-b-round-cell-therapies/

    PHARMACEUTICAL-TECHNOLOGY
    08 Nov 2021
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search